Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Healthcare utilization in patients with acute migraine: pre- and post-treatment with INP104 in a phase 3 study
Headache
Headache Posters (7:00 AM-5:00 PM)
035

Migraine is associated with high rates of emergency department (ER) and urgent care (UC) visits. One of the goals of acute migraine treatment is to optimize self-care and reduce HCRU. INP104 uses the novel, self-administered Precision Olfactory Delivery (POD®) device for efficient drug administration, rapid absorption and high bioavailability.

To assess certain healthcare resource utilization (HCRU) impacts of treating acute migraine with INP104 (dihydroergotamine (DHE) mesylate administered to the upper nasal space by a drug-device combination product) compared to the prior period on best usual care.

An analysis of HCRU data was conducted from the phase 3, multicenter, open-label STOP301 study of INP104 in patients with a documented diagnosis of migraine and at least two attacks/month during the previous six months. HCRU was an exploratory endpoint. Data were patient self-reported for the 12-month baseline period of best usual care at the screening visit and prospectively collected in the patient’s eDiary for the 24-week period on treatment. ER visits, UC visits and hospitalizations were analyzed for the 354 patients who received at least one dose of INP104. Change from baseline for the exposure-adjusted event rate (EAER), defined as the expected number of specific events per 100 person-years of exposure, was calculated. Paired t-tests assessed the significance of these changes .

When compared to the previous 12 months on best usual care, there was a 73% reduction in the event rate of ER visits (9.9 to 2.6; p<0.05), and a 100% reduction in UC visits (7.1 to 0; p<0.01) and hospitalizations (0.6 to 0; p=0.16) while on INP104.  This is the first phase 3 study in acute migraine, to our knowledge, to collect and report HCRU data.

Patients treating acute migraine with INP104 reported significant reductions in HCRU. Treatment with INP104 may benefit patients by reducing or eliminating ER and UC visits.

Authors/Disclosures
Carrie Dougherty, MD (MedStar Georgetown Neurology)
PRESENTER
Dr. Dougherty has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Dougherty has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Dougherty has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Dougherty has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Dougherty has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Dougherty has received personal compensation in the range of $0-$499 for serving as a Consultant for Relivion. The institution of Dr. Dougherty has received research support from Eli Lilly and Co. The institution of Dr. Dougherty has received research support from AbbVie. The institution of Dr. Dougherty has received research support from Axsome.
Sheena K. Aurora, MD (Department of Neurology and Neurological Sciences) Dr. Aurora has received personal compensation for serving as an employee of Impel Neuropharma. Dr. Aurora has stock in Impel Neurpharma.
Stephanie Bariahtaris Stephanie Bariahtaris has received personal compensation for serving as an employee of Impel NeuroPharma. Stephanie Bariahtaris has received stock or an ownership interest from Impel NeuroPharma.
Stephen Bevan Shrewsbury, MD (Impel Pharmaceuticals) Dr. Shrewsbury has received personal compensation for serving as an employee of Impel NeuroPharma. Dr. Shrewsbury has received stock or an ownership interest from Impel NeuroPharma.
Marissa Baker-Wagner (Precision HEOR) Marissa Baker-Wagner has nothing to disclose.
Naomi Sacks Naomi Sacks has nothing to disclose.
Sharon Kautz (PrecisionHEOR) Sharon Kautz has nothing to disclose.
Philip Cyr (PRECISIONheor) Philip Cyr has received personal compensation for serving as an employee of PRECISIONheor.
Benjamin Friedman Benjamin Friedman has nothing to disclose.